|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
WHO00453459X |
003 |
DE-627 |
005 |
20230425165935.0 |
007 |
cr uuu---uuuuu |
008 |
210507s2022 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)WHO00453459X
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2018-002063-26-PT
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)CAIN457M2301
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)2018-002063-26-GB
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a A clinical trial to evaluate treatment with a drug called secukinumab inadult patients who are diagnosed with moderate to severe hidradenitissuppurativa (long term skin disease characterized by the occurrence ofinflamed and swollen lumps)
|b A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa - SUNSHINE
|
264 |
|
1 |
|c 2022
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 26-11-2018, Last updated: 2022-11-24
|
650 |
|
4 |
|a Medical Condition: hidradenitis suppurativa MedDRA version: 20.0Level: LLTClassification code 10020041Term: Hidradenitis suppurativaSystem Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 3
|
650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2022) vom: 09. Mai
|
773 |
1 |
8 |
|g year:2022
|g day:09
|g month:05
|
856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002063-26
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
912 |
|
|
|a SSG-OLC-PHA
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2022
|b 09
|c 05
|